Zobrazeno 1 - 1
of 1
pro vyhledávání: '"11"'
Autor:
Georg H. Fey, Alja J. Stel, Julia Stieglmaier, Harald Wajant, Nicole Mueller, Edwin Bremer, Douwe F. Samplonius, Wijnand Helfrich, Bram ten Cate, Martine E D Chamuleau, Arjan A. van de Loosdrecht
Publikováno v:
Cancer Research, 68(2), 597-604. American Association for Cancer Research Inc.
Cancer Research, 68(2), 597-604. AMER ASSOC CANCER RESEARCH
Bremer, E, ten Cate, B, Samplonius, D F, Mueller, N, Wajant, H, Stel, A J, Chamuleau, M E D, van de Loosdrecht, A A, Stieglmaier, J, Fey, G H & Helfrich, W 2008, ' Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists ', Cancer Research, vol. 68, no. 2, pp. 597-604 . https://doi.org/10.1158/0008-5472.CAN-07-5171
Cancer Research, 68(2), 597-604. AMER ASSOC CANCER RESEARCH
Bremer, E, ten Cate, B, Samplonius, D F, Mueller, N, Wajant, H, Stel, A J, Chamuleau, M E D, van de Loosdrecht, A A, Stieglmaier, J, Fey, G H & Helfrich, W 2008, ' Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists ', Cancer Research, vol. 68, no. 2, pp. 597-604 . https://doi.org/10.1158/0008-5472.CAN-07-5171
The clinical efficacy of the CD20-specific chimeric monoclonal antibody rituximab is significantly hampered by intrinsic or acquired resistance to therapy. Rituximab activates antibody-dependent cellular cytotoxicity/complement-dependent cytotoxicity